• Feature

    Novartis Access in Kenya

    An inside look at Novartis Access in Kenya
  • Improving hypertension management in Ghana - Gladys' story

    Gladys lives in Oborpah, Ghana with her two young children. She has hypertension, a major risk factor for cardiovascular disease, the most deadly non-communicable disease in the world.
  • Media

    Novartis Access - Kenya

    Novartis Access - Kenya

    In October 2015, Novartis Access launched in Kenya and is progressing well with the fourth delivery on its way.
  • Novartis Access - Kenya

    Novartis Access - Kenya

    Peninah is a rice farmer in Kenya. She is one of the first patients to have access to Novartis Access medicines.
  • Novartis Access - Kenya

    Novartis Access - Kenya

    Peninah discovered she had hypertension four years ago and is now going for regular check-ups, taking medicine to help keep her blood pressure in check.
  • Novartis Access - Kenya

    Novartis Access - Kenya

    Peninah chairs the local women’s group in Kiandegwa village, which meets weekly and discusses healthcare topics, from basic sanitation to chronic diseases.
  • Novartis Foundation supported Com-HIP - Ghana

    Novartis Foundation supported Com-HIP - Ghana

    More than one quarter of the adult population in Ghana has hypertension, but only 4% of these hypertensive patients have it under control.
  • Novartis Foundation supported Com-HIP Program - Ghana

    Novartis Foundation supported Com-HIP Program - Ghana

  • Novartis Access Case Study

    Novartis Access Case Study

    See below for PDF version
  • ComHIP Factsheet

    ComHIP Factsheet

    See below for PDF version
  • Kenya confronts Chronic Diseases

Novartis improves ranking in 2016 Access to Medicine Index

Nov 14, 2016

·  Novartis ranks third in 2016 ranking


·  Company tops the industry in access-to-medicine management and capacity building


·  Novartis integrated access strategy addressing all income segments stands out as best practice


Basel, November 14, 2016 Novartis ranked third in the 2016 Access to Medicine Index (up from 4th place in 2014), in recognition of its efforts to improve worldwide access to healthcare.

The Index measures the performance of the top-20 pharmaceutical companies to improve access to medicines and healthcare in developing countries, and is conducted every other year. It covers seven categories, including access-to-medicine management, capacity building, pricing, manufacturing and distribution.

“We share the fundamental aim of the Access to Medicine Index: to close the access gap in developing countries,” said Joseph Jimenez, CEO of Novartis. “We are delighted that our actions have been recognized, but more work is needed. In order to improve access even further, we will continue to work on creating more scalable and sustainable approaches to increase the affordability and availability of medicines to underserved patients.”

Novartis was the industry leader in access-to-medicine management and capacity building.  The company also performed strongly on R&D, with a pipeline spanning all four disease categories in the scope of the Index. Novartis also rose to the top three in pricing, manufacturing and distribution, significantly expanding its equitable pricing strategies.

Two programs in particular were recognized as best practice: Novartis Access, the portfolio of 15 on- and off-patent medicines to fight chronic diseases in lower-income countries; and ComHIP, a program supported by the Novartis Foundation and its partners to evaluate the impact of an innovative healthcare model on hypertension control and self-management in Ghana, Africa. Furthermore, the company’s long-term product donations for liver fluke and leprosy stood out for their reach and broad coverage, according to the Index.

In capacity building, Novartis improved on its already strong performance in 2014. The Index highlights the company’s engagement with the University of Cape Town in South Africa on malaria and tuberculosis drug discovery, as well as the award-winning SMS for Life program, a public-private partnership to manage medicine stocks in sub-Saharan Africa. SMS for Life has been piloted in more than 10,000 healthcare facilities and is being scaled up using smartphones and tablet computers.

Novartis pursues a combination of approaches to expand access to its medicines – philanthropy, zero-profit initiatives and social ventures. In 2015, the company’s access-to-healthcare initiatives reached almost 66 million patients globally, and training and healthcare service programs reached 12 million people.


Media Contacts